Maxxcare Company Limited

Maxxcare Company Limited, established on June 27, 2018, is a Vietnamese pharmaceutical importer headquartered in Tan Binh District, Ho Chi Minh City. The company specializes in the wholesale distribution of pharmaceutical products, focusing on finished formulations such as tablets, capsules, syrups, and injections. With a charter capital of VND 9.2 billion, Maxxcare demonstrates financial stability to support its operations.

Maxxcare's role in Vietnam's pharmaceutical distribution network is that of a primary wholesaler, sourcing finished pharmaceutical formulations from international suppliers and distributing them within the domestic market. This positioning enables the company to meet the growing demand for diverse pharmaceutical products across Vietnam.

Maxxcare Company Limited operates from its headquarters in Tan Binh District, Ho Chi Minh City, Vietnam. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Ho Chi Minh City suggests access to major transportation networks, facilitating efficient distribution throughout Vietnam.

In Vietnam's pharmaceutical supply chain, Maxxcare Company Limited functions primarily as a wholesaler. By importing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in ensuring the availability of a wide range of pharmaceutical products to meet domestic demand. This role is vital for maintaining the supply of essential medications across the country.

Maxxcare Company Limited's sourcing strategy exhibits a high degree of concentration, with 100% of its imports originating from India. This focused approach indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities. The company's top five imported products—Amphotericin, Glimepiride, and others—account for the entirety of its import portfolio, highlighting a specialized product range. The consistent importation of these products over 41 shipments suggests a stable and ongoing relationship with Indian suppliers.

Maxxcare's supply chain resilience is closely tied to its reliance on Indian suppliers. The company's imports are sourced from five unique Indian suppliers, including Inventia Healthcare Limited, Bharat Serums and Vaccines Limited, and others. This diversified supplier base mitigates risks associated with single-source dependency. However, the absence of publicly available information regarding backup suppliers and specific shipping routes indicates potential areas for improvement in enhancing supply chain robustness.

Maxxcare Company's concentrated sourcing from India positions it to benefit from India's competitive pricing and established pharmaceutical manufacturing standards. For Indian exporters, this presents an opportunity to strengthen partnerships with Maxxcare by offering a diverse range of high-quality pharmaceutical formulations that align with the company's import portfolio. Expanding product offerings could further solidify these partnerships and enhance market presence in Vietnam.

In Vietnam, the Ministry of Health (MOH) serves as the primary regulatory authority overseeing pharmaceutical imports. The Law on Pharmacy 2016, along with Decree No. 54/2017/ND-CP, outlines the legal framework governing the importation of pharmaceutical products. These regulations stipulate that only entities with an import license issued by the MOH are authorized to import pharmaceuticals into Vietnam.

To import pharmaceuticals into Vietnam, companies must obtain an import license from the MOH, demonstrating compliance with local business and operational standards. Additionally, importers are required to adhere to Good Storage Practices (GSP) to ensure proper handling and storage conditions of pharmaceutical products. (smartlinklogistics.com.vn)

Imported pharmaceutical products must meet Vietnam's quality control and safety standards, which are progressively aligning with international norms. The MOH mandates that all drugs be registered and approved by the Drug Administration of Vietnam (DAV) and granted Market Authorization (MA) before distribution. This process involves submitting comprehensive documentation, including product composition, manufacturing processes, and stability data.

On December 11, 2023, the Vietnamese government issued Decree No. 88/2023/ND-CP, amending and supplementing provisions of Decree No. 54/2017/ND-CP and Decree No. 155/2018/ND-CP. This decree introduces new regulations concerning the export and import of pharmaceuticals, raw materials for pharmaceutical production, and drug pricing management. Notably, it clarifies import cases of pharmaceutical raw materials and outlines conditions for obtaining import licenses.

Maxxcare Company Limited's import portfolio is concentrated in two therapeutic categories: Antifungals (53.3%) and Diabetes & Endocrine (46.7%). The top two imported products, Amphotericin and Glimepiride, align with these categories, indicating a strategic focus on addressing prevalent health concerns in Vietnam. This targeted approach suggests that Maxxcare is responding to significant market demands for treatments in these therapeutic areas.

Maxxcare's sourcing strategy is centered on importing generic pharmaceutical formulations from India, a country renowned for its extensive pharmaceutical manufacturing capabilities. The company's preference for finished formulations, such as tablets and injections, indicates a focus on ready-to-market products that can be swiftly distributed within Vietnam. This approach allows Maxxcare to efficiently meet domestic demand without the complexities associated with raw material imports.

Based on its product mix, Maxxcare Company Limited primarily serves the wholesale distribution segment of the Vietnamese pharmaceutical market. By importing and distributing finished pharmaceutical formulations, the company ensures that a diverse range of medications is available to various stakeholders, including retail pharmacies, hospitals, and clinics across Vietnam.

There is a realistic opportunity for new Indian suppliers to collaborate with Maxxcare Company Limited. The company's concentrated sourcing from India and its focus on specific therapeutic categories suggest that introducing additional high-quality generic formulations in these areas could meet existing market demands. By aligning with Maxxcare's import portfolio, new suppliers can establish a foothold in the Vietnamese market.

Indian exporters seeking to supply Maxxcare Company Limited must ensure that their pharmaceutical products are registered with the Drug Administration of Vietnam (DAV) and have obtained Market Authorization (MA). Compliance with Good Manufacturing Practice (GMP) standards, recognized by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), is essential. Additionally, adherence to Vietnam's labeling requirements, including Vietnamese language labeling and compliance with Circular 01, is mandatory.

To establish a partnership with Maxxcare Company Limited, Indian exporters should initiate contact by providing detailed product information, including compliance with Vietnamese regulatory standards. Participating in relevant pharmaceutical trade fairs and industry events in Vietnam can facilitate networking opportunities. Understanding and adhering to Vietnam's import licensing requirements and GMP standards will be crucial in building a successful business relationship.